Depsides and depsidones
Medchemexpress LLC Sor-C13 Tfa | 99.3% | 1565.81 (free acid) | 5 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer. This peptide exhibits anticancer activity and is intended for research use only.
- High-affinity TRPV6 antagonist
- IC50 value of 14 nM against TRPV6
- Demonstrated anticancer activity
- Effectively inhibits tumor growth in vivo
- White to off-white solid appearance
- Soluble in H2O and DMSO at 100 mg/mL (with ultrasonic)
- Recommended storage conditions for powder: -80°C for 2 years, -20°C for 1 year
- Recommended storage conditions in solvent: -80°C for 6 months, -20°C for 1 month
Medchemexpress LLC SOR-C13 | 1187852-48-7 | 99.1% | 1565.81 | 10 MG
SOR-C13 is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. It exhibits anticancer activity by targeting TRPV6, a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer.
- High-affinity TRPV6 antagonist with an IC50 value of 14 nM
- Demonstrates anticancer activity
- Targets TRPV6, a non-voltage gated calcium channel
- Effectively inhibits tumor growth in relevant animal models
Medchemexpress LLC Sor-c13 TFA | 1187852-48-7 | 99.3% | 1565.81 | 25 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide. It functions as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA exhibits anticancer activity.
- High-affinity TRPV6 antagonist with an IC50 value of 14 nM.
- Associated with malignancy and poor prognosis in breast cancer.
- Exhibits anticancer activity.
- For research use only.
- Not for sale to patients.
Medchemexpress LLC Sor-C13 Tfa | 99.3% | 1565.81 (free acid) | 10 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. It has shown anticancer activity and targets TRPV6, a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer.
- High-affinity TRPV6 antagonist
- Exhibits anticancer activity
- Targets non-voltage gated calcium channel TRPV6
- Potentially useful in breast cancer research
Apexbio Technology LLC Alogliptin Benzoate 850649-62-6 10mg
Alogliptin Benzoate (CAS 850649-62-6) is a potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) with an IC50 below 10 nM By suppressing DPP-4 activity alogliptin elevates active GLP-1 levels leading to improved glycemic parameters In ob/ob mouse models chronic administration results in dose-dependent reductions in plasma DPP-4 activity non-fasting blood glucose glycated hemoglobin and triglycerides along with increased insulin secretion and pancreatic insulin content Alogliptin Benzoate is widely used in research focused on incretin biology glucose homeostasis and the pharmacological modulation of DPP-4
Medchemexpress LLC SOR-C13 TFA | 1187852-48-7 | 99.3% | 1565.81 (free acid) | 50 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist, exhibiting an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel implicated in malignancy and poor prognosis in breast cancer. This compound has demonstrated anticancer activity.
- High-affinity TRPV6 antagonist with an IC50 of 14 nM.
- TRPV6 is associated with malignancy and poor prognosis in breast cancer.
- Exhibits anticancer activity.
- In vivo studies showed effective inhibition of tumor growth in female NOD/SCID mice with SKOV-3 cells at dosages of 400, 600, and 800 mg/kg (IP; daily; on days 1 to 12).
- Has been investigated in clinical trials for cancer and advanced malignant solid neoplasm.
Medchemexpress LLC Alogliptin Benzoate (SYR 322) | 850649-62-6 | 100.0% | C25H27N5O4 | 200 MG
Alogliptin Benzoate (SYR-322) is a potent, selective, and orally active inhibitor of DPP-4 with an IC50 of <10 nM, exhibiting over 10,000-fold selectivity over DPP-8 and DPP-9. It is suitable for research into type 2 diabetes.
- Potent, selective, and orally active inhibitor of DPP-4.
- Inhibits LPS-induced extracellular signal-regulated kinase (ERK) phosphorylation in U937 cells.
- Inhibits LPS-stimulated MMP-1 secretion and mRNA expression mediated by the ERK pathway in U937 cells.
- Improves glucose tolerance and increases plasma insulin levels in female Wistar fatty rats.
- Reduces infarction area and improves brain vascular integrity in middle cerebral artery occlusion (MCAO) mice.
Medchemexpress LLC Fotagliptin benzoate | 1403496-40-1 | 99.2% | 464.49 g·mol⁻1 | C24H25FN6O3 | 5MG
Fotagliptin benzoate is a research-grade dipeptidyl peptidase-4 (DPP-4) inhibitor provided as the benzoate salt for preclinical and biochemical studies related to type 2 diabetes research. It is supplied as a solid powder and in small analytical vial sizes for laboratory use.
Medchemexpress LLC Alogliptin Benzoate (Standard) | 850649-62-6 | 99.3% | C25H27N5O4 | 5 MG
Alogliptin Benzoate (Standard) is an analytical standard of Alogliptin (Benzoate) for research and analytical applications. It is a potent, selective, and orally active inhibitor of DPP-4 with an IC50 of <10 nM, exhibiting over 10,000-fold selectivity over DPP-8 and DPP-9. This analytical standard is suitable for type 2 diabetes research and commonly employed in qualitative, quantitative, and methodological research experiments using techniques like HPLC, GC, and MS.
- Analytical standard for research and analytical applications
- Potent, selective, and orally active DPP-4 inhibitor
- IC50 of <10 nM
- Exhibits over 10,000-fold selectivity over DPP-8 and DPP-9
- Suitable for type 2 diabetes research
- Used in qualitative, quantitative, and methodological research experiments
- Compatible with HPLC, GC, and MS techniques